Van ECK Associates Corp Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Van ECK Associates Corp increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 93,406 shares of the company’s stock after acquiring an additional 9,824 shares during the quarter. Van ECK Associates Corp owned approximately 0.09% of Neurocrine Biosciences worth $12,750,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. CWM LLC raised its position in shares of Neurocrine Biosciences by 15.1% during the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock worth $908,000 after purchasing an additional 1,035 shares during the last quarter. Creative Planning increased its stake in Neurocrine Biosciences by 12.3% during the 3rd quarter. Creative Planning now owns 12,999 shares of the company’s stock worth $1,498,000 after buying an additional 1,426 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Neurocrine Biosciences by 12.7% during the third quarter. Vontobel Holding Ltd. now owns 14,590 shares of the company’s stock valued at $1,681,000 after acquiring an additional 1,639 shares during the last quarter. Trust Point Inc. lifted its position in shares of Neurocrine Biosciences by 22.0% in the third quarter. Trust Point Inc. now owns 1,935 shares of the company’s stock valued at $223,000 after acquiring an additional 349 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Down 1.6 %

Shares of NASDAQ NBIX opened at $115.02 on Friday. The business’s 50 day moving average is $137.83 and its two-hundred day moving average is $130.54. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a report on Tuesday, February 11th. They issued a “hold” rating and a $138.00 price objective on the stock. Royal Bank of Canada decreased their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research note on Friday, February 7th. UBS Group upped their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. HC Wainwright decreased their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Barclays upped their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $166.90.

Insider Transactions at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 236,600 shares of company stock valued at $34,348,261. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.